Gelteq Ltd income statement

In fiscal 2025, Gelteq Ltd reported revenue of $107,317, up 99.7% on the year before, operating income of −$3.6m (a -3317.7% margin) and net income of −$4.3m, or −$0.47 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Gelteq Ltd: income statement, annual
Fiscal year	2023Jun 2023	2025Jun 2025
Revenue	54	107
Cost of revenue	—	75
Gross profit	—	33
Research and development	448	407
Operating income	−2,088	−3,560
Interest expense	271	1,242
Income before tax	−2,360	−4,305
Net income	−2,360	−4,305
Diluted EPS	−$0.30	−$0.47
Diluted shares (average)	8m	9m
EBITDA	−1,263	−2,768

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AKAN vs GELS GELS vs PRFX GELS vs SCNX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Gelteq Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Gelteq Ltd.